361P - A retrospective analysis of platinum-based neoadjuvant chemotherapy for local advanced triple negative breast cancer

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Cytotoxic agents
Breast Cancer
Biological therapy
Presenter Fei Fei
Authors F. Fei1, Y. Du2, X. Gu2, C. Chen2, J. Wu2, Z. Shao2
  • 1Medical Department, Shanghai Cancer Center Fudan University, 200032 - Shanghai/CN
  • 2Breast Surgery, Shanghai Cancer Center Fudan University, Shanghai/CN



We retrospectively analyzed platinum-based neoadjuvant chemotherapy for LATNBC to compare survival outcomes between patients with PCR and with non-PCR. Furthermore, the disease free survival of LATNBC patients with PCR continuously receiving primary regimen as adjuvant setting had comparative advantage concerning that of “PCR” patients switching to other regimens as adjuvant setting as well as those without any chemotherapy after sugery.

Patients and methods

124 women with stage II or III TNBCs experienced platinum-based regimens as neoadjuvant chemotherapy from Nov 1, 2007 to Dec 31, 2011. All patients were divided into the two groups, who were with and without PCR in the pathological reports after surgery. According to the adjuvant settings for LATNBC patients with PCR, the three arms were determined as continuous primary regimen (the same as neoadjuvant) arm, no more chemotherapy arm and switching arm. Disease free survival was computed using the Kaplan-Meier product limit method.


We presented a retrospective chart review of 124 LATNBC patients who underwent platinum-based neoadjuvant chemotherapy in our hospital. Fifty (40.32%) of those patients receiving neoadjuvant chemotherapy had PCR when they underwent surgery. After controlling for covariates associated with survival, patients undergoing neoadjuvant chemotherapy with residual tumor had significantly worse survival than patients with PCR (HR = 0.37,P < 0.05). Of 50 patients with PCR confirmed by surgery, the disease free survival of 24 cases switching to other regimens in the adjuvant setting was significantly better than that of 24 cases continuously receving primary regimens in the adjuvant setting (HR= 0.51, P = 0.025)and that of 2 cases with no more chemotherapy(HR= 0.58, P = 0.017)


Patients with PCR had statistically significantly better clinical survival than those with non-PCR after platinum-based neoadjuvant settings.So far, if LATNBC patients with PCR after platinum-based neoadjuvant chemotherapy, they might have better clinical survival if they receive switching regimens than to receive primary regimens and to continue with no additional chemotherapy after surgery. A randomized prospective study needs to be carried out to strengthen the results because of statistical bias.


All authors have declared no conflicts of interest.